Question : BLOOD DISORDERS



(a) the number of people suffering from sickle cell anaemia, thalassemia and haemophilia in the country, State/UT-wise;

(b) whether the Government has conducted any survey/study in this regard, if so, the details and the outcome thereof, State/UT-wise;

(c) whether the Government proposes to launch a programme for prevention and control of sickle cell anaemia, thalassemia and haemophilia in the country, if so, the details thereof along with the time by which the programme is likely to be launched;

(d) the extent of financial and technical assistance/commodities being provided by the Government to the States/UTs for the investigation, prevention and control of the aforesaid blood disorders;

(e) whether the Government has entered into agreement with Japan to help fight with the aforesaid hereditary blood disorders, if so, the details thereof; and

(f) the measures being taken by the Government to promote research in order to develop therapy of hereditary blood disorders through stem cell in the country?

Answer given by the minister



THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI JAGAT PRAKASH NADDA)

(a) & (b): Data regarding number of patients suffering from sickle cell anemia, thalassemia and haemophilia in the country is not maintained centrally. No survey/study has been con- ducted by Union Government.

(c): Currently, there is no such proposal.

(d): Under the National Health Mission (NHM), the Government of India provides financial support to States/UTs for strengthening of healthcare systems including support for pre- vention and control of sickle cell anemia, thalassemia and haemophilia in the country. In the Financial Year 2014-15, Rs. 6192.83 Lakhs has been approved for the States of Uttarakhand, Gujarat, Kerala, Maharashtra, Odisha and Uttar Pradesh for prevention and control of the aforesaid blood disorders.

(e): Government has not entered into agreement with Japan to help fight with the aforesaid hereditary blood disorders.

(f): No research is currently being done to develop therapy of hereditary blood disorders through stem cell in the country.